Characterization and HIV-1 fusion inhibitory properties of monoclonal fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41

Journal of Molecular Biology

Volumn 353, Issue 5, 2005, Pages 945-951

  Louis, John M ^a   Bewley, Carole A ^a   Gustchina, Elena ^a   Aniana, Annie ^a   Clore, G Marius ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Fusion inhibitors; gp41; HIV envelope; HIV 1 fusion; Virus

Indexed keywords

ANTIBODY; ANTIGEN; DISULFIDE; EPITOPE; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN F(AB) FRAGMENT; POLYPEPTIDE;

ANTIBODY SPECIFICITY; ARTICLE; BACTERIOPHAGE; CELL FUSION; CONFORMATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; PRIORITY JOURNAL; REPORTER GENE; THERMOSTABILITY; VACCINIA VIRUS; VIRUS ENVELOPE; WESTERN BLOTTING;

HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA VIRUS;

EID: 27144451245     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2005.09.044     Document Type: Article

References (34)

1. E.O. Freed, and M.A. Martin The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection J. Biol. Chem. 270 1995 23883 23886
2. J.P. Moore, A. Trkola, and T. Dragic Co-receptors for HIV-1 entry Curr. Opin. Immunol. 7 1997 551 562
3. D.M. Eckert, and P.S. Kim Mechanisms of viral membrane fusion and its inhibition Annu. Rev. Biochem. 70 2001 777 810
4. D.C. Chan, and P.S. Kim HIV entry and its inhibition Cell 93 1998 681 684
5. R.A. Furuta, C.T. Wild, Y. Weng, and C.D. Weiss Capture of an early fusion-active conformation of HIV-1 gp41 Nature Struct. Biol. 5 1998 276 279
6. T. Koshiba, and D.C. Chan The pre-fusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions J. Biol. Chem. 278 2003 7573 7579
7. C.T. Wild, D.C. Shugars, T.K. Greenwell, C.B. McDanal, and T.J. Matthews Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection Proc. Natl Acad. Sci. USA 91 1994 9770 9774
8. D.C. Chan, C.T. Chutkowski, and P.S. Kim Evidence that a prominent cavity in the coiled-coil of HIV type 1 gp41 is an attractive drug target Proc. Natl Acad. Sci. USA 95 1998 15613 15618
9. E. Gustchina, G. Hummer, C.A. Bewley, and G.M. Clore Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2 and SIV J. Med. Chem. 48 2005 3036 3044
10. M.J. Root, M.S. Kay, and P.S. Kim Protein design of an HIV-1 entry inhibitor Science 291 2001 884 888
11. CCG-gp41, a chimeric gp41 molecule with nanomolar fusion inhibitory activity J. Biol. Chem. 276 2001 29485 29489
12. J.M. Louis, I. Nesheiwat, L.C. Chang, G.M. Clore, and C.A. Bewley Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion J. Biol. Chem. 278 2003 20278 20285
13. C.A. Bewley, J.M. Louis, R. Ghirlando, and G.M. Clore Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41 J. Biol. Chem. 277 2002 14238 14245
14. A. Knappik, L. Ge, A. Honegger, P. Pack, M. Fisher, and G. Wellnhofer Fully synthetic human combinatorial antibody libraries (HuCAL) based on molecular consensus frameworks and CDRs randomized with trinucleotides J. Mol. Biol. 296 2000 57 86
15. T. Kretzschmar, and T. von Rüden Antibody discovery: phage display Curr. Opin. Biotechnol. 13 2002 598 602
16. B. Krebs, R. Rauchenberger, S. Reiffert, C. Rothe, M. Tesar, and E. Thomassen High-throughput generation and engineering of recombinant human antibodies J. Immunol. Methods 254 2001 67 84
17. R. Ostendorp, C. Frisch, and M. Urban Generation, engineering and production of human antibodies using HuCAL G. Subramanian Antibodies: Novel Technologies and Therapeutics vol. 2 2004 Kluwer Academic/Plenum Publishers New York
18. P. Pack, and A. Plücktun Mini-antibodies: use of amphiphatic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli Biochemistry 31 1992 1579 1584
19. R. Rauchenberger, E. Borges, E. Thomassen-Wolf, E. Rom, R. Adar, and Y. Vaniv Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3 J. Biol. Chem. 278 2003 38194 38205
20. D.C. Chan, D. Fass, J.M. Berger, and P.S. Kim Core structure of gp41 from HIV envelope glycoprotein Cell 89 1997 263 273
21. W. Weissenhorn, A. Dessen, S.C. Harrison, J.J. Skehel, and D.C. Wiley Atomic structure of the ectodomain from HIV-1 gp41 Nature 387 1997 426 430
22. K. Tan, J. Liu, S. Wang, S. Sgen, and M. Lu Atomic structure of a thermostable subdomain of HIV-1 gp41 Proc. Natl Acad. Sci. USA 94 1997 12303 12308
23. A.S. Dimitrov, J.M. Louis, C.A. Bewley, G.M. Clore, and R. Blumenthal Conformational changes in HIV-1 gp41 in the course of HIV-1 Env-mediated fusion and inactivation Biochemistry 2005 In the press
24. K. Salzwedel, E. Smith, B. Dey, and E.A. Berger Sequential CD4-receptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activity of antibodies against cryptic conserved epitopes on gp120 J. Virol. 74 2000 326 333
25. S. Zolla-Pazner Identifying epitopes of HIV-1 that induce protective antibodies Nature Rev. Immunol. 4 2004 199 210
26. J. Cotropia, K.E. Ugen, S. Kilks, K. Broliden, P.A. Broliden, and J.A. Hoxie A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates J. Acqu. Immun. Def. Syndr. Hum. Retrovirol. 12 1996 221 232
27. C.E. Hioe, S. Xu, P. Chigurupati, S. Burda, C. Williams, M.K. Gorny, and S. Zolla-Pazner Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies Int. Immunol. 9 1997 1281 1290
28. F. Ferrantelli, M. Kitabwalla, R.A. Rasmussen, C. Cao, T.-C. Chou, and H. Katinger Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies: implications for acquired immunodeficiency syndrome vaccine J. Infect. Dis. 189 2004 71 74
29. Trkola, A., Pomales, A. B., Yuan, H., Korber, B., Maddon, P. J., Allaway, G. P., et al. (1995). Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69, 6609-6617.
30. Zwick, M. B., Labrijn, A. F., Wang, M., Spenlehauer, C., Ollmann-Saphire, E., Binley, J. M., et al. (2001). Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892-10905.
31. M.B. Zwick, R. Jensen, S. Church, M. Wang, G. Stiegler, and R. Kunert Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize gp41 J. Virol. 79 2005 1252 1261
32. S. Jiang, K. Lin, and M. Lu A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein J. Virol. 72 1998 10213 10217
33. Y. Feng, C.C. Broder, P.E. Kennedy, and E.A. Berger HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor Science 272 1996 872 877
34. C.C. Broder, and E.A. Berger Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+T-cell lines versus primary macrophages Virology 259 1995 1 6